AHNTI is one of the leading international meeting places for the animal health industry, bringing together global pharmaceutical companies, innovators, investors, regulatory stakeholders and commercial partners from across the sector. During the congress, Immuvera held a series of meetings with major veterinary pharmaceutical companies as well as selected investor groups active in animal health and life sciences.

The conference highlighted continued momentum in companion animal health, with particular emphasis on innovation, strategic partnerships, new therapeutic modalities and the growing importance of differentiated products addressing significant unmet medical needs. Immuvera believes these industry themes are highly relevant to the company’s ongoing development of Nebumet, its inhaled immunotherapy platform targeting lung metastases in dogs.

“AHNTI was a highly relevant arena for Immuvera to engage with both industrial and financial stakeholders in animal health. The meetings in London reinforced our view that the market is increasingly focused on innovative and differentiated therapies in companion animals, and that there is strong interest in new approaches within veterinary oncology,” said Jørund Sollid, CEO of Immuvera Therapeutics.

Immuvera’s attendance at AHNTI forms part of the company’s broader strategy to build visibility within the global animal health ecosystem, strengthen industry relationships and position Nebumet for future clinical, regulatory and commercial progress.

About Immuvera Therapeutics
Immuvera Therapeutics is a Norwegian veterinary oncology company developing inhaled immunotherapies for metastatic cancer in dogs. Its lead product, Nebumet, is an off-the-shelf inhaled immunotherapeutic candidate designed to prevent and treat lung metastases, with oral malignant melanoma as the first target indication.